• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

    4/10/24 12:00:00 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGS alert in real time by email

    ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (NASDAQ:ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis' therapeutic programs and its suite of product development and GMP cell processing services. The collaboration's goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.

    By combining Germfree's expertise in designing, manufacturing, and maintaining advanced manufacturing facility environments with Orgenesis' cutting-edge processes and analytical development capabilities, the partnership seeks to significantly reduce the production costs of cell and gene therapy products. The ultimate goal is to enable broader adoption of life-saving treatments.

    Vered Caplan, CEO of Orgenesis, stated, "Under the agreement, Orgenesis and Germfree will join forces to co-market Orgenesis' decentralized Octomera service platform, and its Octomera Mobile Processing Units and Labs (OMPULs™) globally. The partnership marks a significant milestone in the bio-manufacturing industry, as the industry begins to pivot to the paradigm-shifting distributed processing of cell and gene therapies (CGTs). Germfree will be marketing, manufacturing, and servicing OMPULs as part of its modular cleanroom fleet, enabling Orgenesis to focus on its therapeutic pipeline with an emphasis on immuno-oncology. We are delighted to work with Germfree to meet the growing demand for our platform."

    Victor Miller, CFO of Orgenesis, remarked on the financial and strategic significance of the partnership, stating, "This collaboration significantly supports Orgenesis' infrastructure growth requirements while immediately providing a commercial footprint that will significantly impact market expansion opportunities for the partnership."

    Carol Houts, Chief Strategy Officer at Germfree, highlighted the innovative potential of the partnership, "Our collaboration with Orgenesis transcends traditional boundaries, setting a new standard for the industry. By harnessing the power of digital workflows and advanced quality management systems, we believe that we are not just streamlining production but revolutionizing it. This partnership is expected to foster innovation, particularly in how we approach and execute cell and gene therapy manufacturing. Moreover, our joint efforts with regulatory authorities worldwide are expected to ensure that our advancements not only meet, but exceed, global standards. The synergy between Germfree and Orgenesis paves the way for a future where regulatory collaboration and digital innovation ensure that life-saving therapies are developed and delivered with high efficiency and quality."

    Kevin Kyle, CEO of Germfree, shared his insights on the collaboration, "Our strategic partnership with Orgenesis is a cornerstone in the continuation of our mission to advance healthcare solutions globally. By integrating Germfree's modular cleanroom technology with Orgenesis' innovative cell and gene therapy programs, we are setting a new benchmark for efficiency and accessibility in the treatment of life-threatening conditions. This collaboration is not just about enhancing production capabilities; it's about creating a paradigm shift in how cell therapies are developed, produced, and delivered to those in dire need. Together, we are building the foundation for a future where advanced medical treatments are no longer a privilege, but a right, accessible to everyone, everywhere."

    For more information about Germfree and Orgenesis and their strategic partnership, please visit www.germfree.com and www.orgenesis.com.

    About Germfree

    Germfree is a global leader in the design, manufacture, and maintenance of modular cleanroom environments. With decades of global expertise in serving the biopharmaceutical industry, Germfree specializes in providing advanced solutions that enhance the safety, efficiency, and sustainability of critical healthcare manufacturing processes.   Germfree is continuing to invest in cleanroom design and manufacturing solutions and is committed to providing innovative solutions, with the goal of improving patient access to critical medicines. Germfree is backed by the healthcare growth equity investor, EW Healthcare Partners. www.germfree.com

    About Orgenesis

    Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization, while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger number of patients more cost effectively and with better outcomes through great science and decentralized production.

    Notice Regarding Forward-Looking Statements

    This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our decentralized cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our decentralized cell therapy processing, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us, our ability to remain listed on Nasdaq and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

    Investor relations contact for Orgenesis:

    Crescendo Communications, LLC

    Tel: 212-671-1021

    Email: [email protected]

    Communications contact for Orgenesis:

    IB Communications

    Michelle Boxall

    Media Contact for Germfree:

    Lauren Blum, Content Marketing Manager at Germfree

    +1 386-265-4300

    [email protected]



    Primary Logo

    Get the next $ORGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORGS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ORGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Safier Jacob bought $16,883 worth of shares (30,000 units at $0.56) and sold $16,259 worth of shares (30,000 units at $0.54) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/4/24 6:48:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $3,332 worth of shares (10,100 units at $0.33) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:32:21 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $213,280 worth of shares (365,140 units at $0.58) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:31:52 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    SEC Filings

    See more
    • Orgenesis Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Orgenesis Inc. (0001460602) (Filer)

      6/6/25 4:30:16 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Orgenesis Inc.

      NT 10-Q - Orgenesis Inc. (0001460602) (Filer)

      5/16/25 4:30:31 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Orgenesis Inc.

      25-NSE - Orgenesis Inc. (0001460602) (Subject)

      5/8/25 5:21:49 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orgenesis Provides Third Quarter 2024 Business Update

      GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentralized approach. This model is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. We are dedicated to expanding our clinical initiatives and deepening gl

      11/13/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Commences Trading on OTCQX® Best Market

      Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficienc

      10/21/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Announces Reverse Stock Split

      GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq C

      9/23/24 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)

      3 - Orgenesis Inc. (0001460602) (Issuer)

      3/18/25 4:06:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Vider Itzhak

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:24 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Adler Yaron

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:29 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Financials

    Live finance-specific insights

    See more
    • Orgenesis Provides Second Quarter 2024 Business Update

      GERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended June 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "After more than a decade of parallel efforts—on one hand, establishing robust capabilities in cell therapy production by initially serving the industry in a centralized manner and later integrating these capabilities into a decentralized platform, and on the other, forming partnerships through joint ve

      8/8/24 4:05:00 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

      GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners ("Metalmark"), for the acquisition of its approximate 25% stake in Octomera LLC ("Octomera"), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027,

      1/31/24 9:15:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Provides Business Update for Second Quarter of 2023

      Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, "We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform. We recently rebranded the POC Servic

      8/11/23 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Leadership Updates

    Live Leadership Updates

    See more
    • Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

      GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced therapeutic POCare services and facilities supply business, Octomera. The appointment of Gerhard Bauer as the Vice President of Global Product Implementation at Octomera has been made to enhance the existing process development, regulatory, engineering, equipment, and data/technical service offering and POCare Center hubs. He is also an active contributor to the evolution of the flexible facilities format, Octomera Mobile Process Labs & Units (OMPULs) and network, which allow the

      9/6/23 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

      GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023. Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical devic

      7/13/23 8:30:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education

      New York, March 08, 2021 (GLOBE NEWSWIRE) -- - Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here - Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs click here - QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) updates on Opemiska drill progress and names new independent director click here - AIM ImmunoTech Inc (NYSEAMERICAN:AIM) doses first healthy subject in intranasal Ampligen coronavirus study click here - Alpine 4 Technologies Inc (OTCQB:ALPP) say

      3/8/21 2:36:14 PM ET
      $TCON
      $ORGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ORGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:51:18 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:50:26 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Orgenesis Inc. (Amendment)

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      2/14/24 8:16:04 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care